Not sure I'd be reading too much into that reporting. Suspect it is just a journo that is relatively new to reporting on publicly listed biotech companies including the boilerplate language on risks into their story. it's not wrong per se, just a bit unusual. But is not to my mind indicative of a higher level of risk. Stand to be corrected if this language has altered to reflect higher risk levels in this quarterly but I doubt it - not least because the CR has lowered these risks.
Not sure I'd be reading too much into that reporting....
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
0.050(4.59%) |
Mkt cap ! $1.301B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.14 | $1.08 | $6.654M | 5.972M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1330 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 171164 | 10 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |